Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris.

Author: CragerMichael, McKayCharles R, RichMichael W

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Extended-release ranolazine is effective and safe for patients with angina, regardless of age. However, adverse effects are more common in older patients.
Paper Details　
Original Abstract of the Article :
This analysis examined the safety and efficacy of extended-release ranolazine among patients aged 70 years or older (n=363) compared with patients younger than 70 years (n=1024) enrolled in 2 large multinational prospective clinical trials. The primary end points were exercise capacity and number of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1076-7460.2007.07119.x

データ提供：米国国立医学図書館（NLM）

Evaluating the Safety and Efficacy of Extended-Release Ranolazine in Older Adults with Chronic Stable Angina

This study is a comprehensive exploration into the world of cardiovascular health, focusing on the efficacy and safety of extended-release ranolazine in older adults with chronic stable angina pectoris. The researchers utilized a large, multinational prospective clinical trial to compare the effects of ranolazine on exercise capacity and the frequency of angina episodes in older adults versus younger adults. Their findings provide valuable insights into the potential benefits and risks of ranolazine treatment in this population.

Similar Efficacy Across Age Groups

The study revealed that ranolazine demonstrated comparable efficacy in both older and younger patients, offering a glimmer of hope for managing angina across generations. The researchers observed that the mean exercise duration increased significantly in both age groups when treated with ranolazine compared to placebo. This suggests that ranolazine can be an effective treatment option for improving exercise tolerance in individuals with chronic stable angina, regardless of age. It's like finding a hidden spring of relief in the vast desert of angina symptoms.

Increased Adverse Effects in Older Adults

While the study found similar efficacy across age groups, it also revealed that older adults were more likely to experience adverse effects. This is an important consideration when prescribing ranolazine, as it highlights the need for careful monitoring and individual risk assessment. It's like navigating a desert landscape; older adults may face more challenges, but the journey can still be rewarding.

Dr.Camel's Conclusion

The research sheds light on the complexities of managing angina in older adults. It emphasizes the importance of individualized treatment plans and the need to carefully balance the potential benefits and risks of ranolazine therapy. It's a reminder that even in a vast desert of medical challenges, finding the right approach can lead to a healthier and more fulfilling life for patients.

Date :
  1. Date Completed 2007-10-16
  2. Date Revised 2019-11-10
Further Info :

Pubmed ID

17617747

DOI: Digital Object Identifier

10.1111/j.1076-7460.2007.07119.x

Related Literature

Article Analysis
・Side Effects of ranolazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.